Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-03-27 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于减少注册资本完成工商变更登记并换发营业执照的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Changchun High-tech Industry Group Co., Ltd. regarding the completion of a reduction in registered capital and the related business registration change, including the issuance of a new business license. It references board and shareholder meetings where the capital reduction and related amendments were approved. The document is short (696 characters) and serves as a formal notice of a capital change event rather than a detailed financial report or analysis. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. The content fits the category of a Share Issue/Capital Change announcement, as it deals with changes in registered capital and related corporate filings.
2025-03-27 Chinese
关于子公司GenSci120注射液新药临床试验申请获得美国食品药品监督管理局默示许可的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding its subsidiary's new drug clinical trial application approval by the US FDA. It details the drug GenSci120, its clinical trial approval status, and potential impacts and risks. The document is short (1681 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or detailed report content. It is not a report publication announcement since it does not mention an attached report or provide a link to a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval and company disclosures.
2025-03-20 Chinese
关于子公司聚乙二醇重组人生长激素注射液增加国内同品种已批准适应症补充申请获得国家药监局批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the approval by the National Medical Products Administration (国家药品监督管理局) of a supplementary application for additional approved indications for a subsidiary's pharmaceutical product. The content focuses on regulatory approval and its impact on the company, with no financial statements or detailed financial performance data. The document length is short (1005 characters) and it is a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a voting result, board change, or capital update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-04 Chinese
关于回购股份进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 长春高新技术产业（集团）股份有限公司. It details the number of shares repurchased, prices, compliance with regulations, and references previous announcements about the repurchase plan. The document length is short (1349 characters) and focuses on the update of the share buyback activity, not a full financial report or earnings release. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2025-03-03 Chinese
关于亮丙瑞林注射乳剂上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of the application for the marketing approval of a pharmaceutical product (亮丙瑞林注射乳剂) by the National Medical Products Administration. It details the product, regulatory approval process, clinical study results, and market plans. The document is short (1494 characters) and serves as an official announcement of a regulatory acceptance event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. It is not a certification or officer attestation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-19 Chinese
关于部分回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of cancellation of repurchased shares and the resulting change in the company's share capital. It details the number of shares cancelled, the dates of board and shareholder meetings approving the cancellation, and the impact on the company's share capital structure. There is no financial statement or detailed financial analysis present, and the document is relatively short (1991 characters). This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback and cancellation of its own shares.
2025-02-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.